# Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

> **NCT06819735** · PHASE1,PHASE2 · RECRUITING · sponsor: **Domain Therapeutics Australia Pty Ltd** · enrollment: 125 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** DT-7012
- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT06819735
- **Lead sponsor:** Domain Therapeutics Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-09
- **Final completion:** 2028-01
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06819735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06819735, "Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06819735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*